INDIANAPOLIS, June 16 (UPI) — U.S. drug maker Eli Lilly and Co. said it stopped its Phase II study of a promising drug to slow Alzheimer’s disease over concerns about potential liver damage.
Jan M. Lundberg, executive vice president for science and technology and president of Lilly Research Laboratories, said the cases of abnormal liver biochemical tests were identified as part of routine monitoring. Lilly will continue to monitor all participants with abnormal liver biochemical tests, Lundberg said.
The Alois Alzheimer Foundation 